PharmaCyte Biotech, Inc. (PMCB)
USD 1.6
(-4.19%)
USD 1.6
(-4.19%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 8.52 Million | 6.45 Million | 4.39 Million | 3.62 Million | 3.82 Million | 4.1 Million |
| Selling, General and Administrative Expenses | 2.11 Million | 5.98 Million | 3.7 Million | 2.7 Million | 3.52 Million | 3.64 Million |
| Research and Development Expenses | 407.43 Thousand | 468.53 Thousand | 690.93 Thousand | 916.24 Thousand | 301.22 Thousand | 460.05 Thousand |
| Other Expenses | 5.99 Million | 202 Thousand | -4283.00 | -1188.00 | -40.00 | 33.4 Thousand |
| Cost and Expenses | 6.52 Million | 6.45 Million | 4.39 Million | 3.62 Million | 3.82 Million | 4.1 Million |
| Operating Income | -8.52 Million | -6.45 Million | -4.39 Million | -3.62 Million | -3.82 Million | -4.1 Million |
| Interest Expense | - | - | 509.00 | 3046.00 | 453.00 | - |
| Income Tax Expense | - | -1.93 Million | -153.36 Thousand | 3046.00 | 453.00 | -33.4 Thousand |
| Earnings before Tax | 333.76 Thousand | -4.31 Million | -4.23 Million | -3.55 Million | -3.82 Million | -4.06 Million |
| Net Income | 333.76 Thousand | -4.31 Million | -4.08 Million | -3.55 Million | -3.82 Million | -4.06 Million |
| Earnings Per Share Basic | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 |
| Earnings Per Share Diluted | -1.80 | -0.22 | -0.26 | -2.46 | -4.23 | -5.55 |
| Weighted Average Shares Outstanding | 9.58 Million | 19.48 Million | 15.52 Million | 1.44 Million | 903.81 Thousand | 733.4 Thousand |
| Weighted Average Shares Outstanding (Diluted) | 9.58 Million | 19.48 Million | 15.52 Million | 1.44 Million | 903.81 Thousand | 733.4 Thousand |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | - | - | - | -3.82 Million | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 8.52 Million | 1.16 Million | 1.86 Million | 1.4 Million | 2.07 Million | 6.45 Million |
| Selling, General and Administrative Expenses | - | 1.07 Million | 1.74 Million | 1.09 Million | 1.73 Million | - |
| Research and Development Expenses | - | 94.18 Thousand | 126.73 Thousand | 82.03 Thousand | 104.48 Thousand | - |
| Other Expenses | 5.99 Million | 4.78 Million | -253.00 | -765.00 | -1849.00 | 202 Thousand |
| Cost and Expenses | 8.52 Million | 1.16 Million | 1.86 Million | 1.4 Million | 2.07 Million | 6.45 Million |
| Operating Income | -8.52 Million | -1.16 Million | -1.86 Million | -1.4 Million | -2.07 Million | -6.45 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | 1.77 Million | -1868.95 | -894.18 Thousand | -875.87 Thousand | -1.93 Million |
| Earnings before Tax | -17.23 Million | 1.34 Million | -619.53 Thousand | 2.78 Million | -3.18 Million | -4.31 Million |
| Net Income | -17.23 Million | 1.34 Million | -619.53 Thousand | 2.78 Million | -3.18 Million | -4.31 Million |
| Earnings Per Share Basic | - | 0.17 | -0.07 | 0.32 | -0.25 | - |
| Earnings Per Share Diluted | - | 0.17 | -0.07 | 0.32 | -0.25 | - |
| Weighted Average Shares Outstanding | 9.58 Million | 8.03 Million | 8.6 Million | 8.76 Million | 12.6 Million | 19.48 Million |
| Weighted Average Shares Outstanding (Diluted) | 9.58 Million | 8.03 Million | 8.6 Million | 8.76 Million | 12.6 Million | 19.48 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | -1.16 Million | -1.86 Million | -4.71 Million | -93.32 Thousand | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
7389
1579
FQVLF
TMG
2667
CTLP